Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The REGENXBIO Inc. (RGNX) SEC filings page brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer focused on AAV gene therapy, REGENXBIO uses current reports on Form 8-K and other filings to communicate material information about its operations, clinical programs, collaborations and financial condition.
Recent 8-K filings illustrate how the company reports key developments. One Form 8-K describes the issuance of a press release covering financial results and operational highlights for the quarter ended September 30, 2025, including updates on late-stage programs such as RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for MPS II and surabgene lomparvovec (ABBV-RGX-314, sura-vec) for retinal disease. Another 8-K details the FDA’s extension of the Prescription Drug User Fee Act (PDUFA) action date for the RGX-121 Biologics License Application for MPS II, moving the date to February 8, 2026 to allow review of additional data.
REGENXBIO also uses Form 8-K to disclose significant collaboration changes. An 8-K filed in August 2025 outlines a first amendment to the collaboration and license agreement with AbbVie, which modifies the development plan and milestone structure for the diabetic retinopathy program using suprachoroidal delivery and adds further AbbVie-led investment in the subretinal wet AMD program. The filing explains new milestone payment terms tied to first patient dosing in registration-enabling trials and references a joint press release attached as an exhibit.
On this page, investors can review such 8-Ks alongside other SEC documents to understand how REGENXBIO reports clinical milestones, regulatory interactions, collaboration amendments and financial results. Stock Titan’s tools can help surface the most recent filings, while AI-powered summaries can clarify the main points of lengthy documents, highlight items such as PDUFA date changes or collaboration amendments, and make it easier to follow how these disclosures relate to the company’s gene therapy pipeline and RGNX stock.
REGENXBIO Inc. is asking shareholders to vote at its May 29, 2026 Annual Meeting on director elections, ratification of PwC as auditor, an advisory "say-on-pay" vote, and two related stock option exchange proposals for non-executive and executive employees. The company highlights 2025 progress: completion of key trial enrollments 1,200 participants in ABBV-RGX-314 pivotal trials), a strategic partnership with Nippon Shinyaku with a $110.0 million upfront payment, and a $150.0 million royalty bond close with up to $250.0 million capacity. The company reported $240.9 million in cash, cash equivalents and marketable securities as of year-end 2025. The proxy also discloses regulatory setbacks: the FDA placed the RGX-121 program on clinical hold in January 2026 and issued a Complete Response Letter in February 2026; the company is developing responses to both actions.
REGENXBIO Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating it beneficially owns 0 shares of Common Stock (CUSIP 75901B107) and holds 0% of the class. The filing says an internal realignment on January 12, 2026 caused disaggregated reporting by subsidiaries that previously reported with Vanguard.
REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve a dispute related to their 2009 license sublicensing arrangement. Under the agreement, REGENXBIO will pay $10.0 million to GSK within three business days of the agreement’s effective date for alleged underpayment of sublicense fees on amounts received from sublicensees, including royalties. The parties are granting each other mutual releases for all past claims connected to the sublicense and certain specified future claims, while REGENXBIO will continue paying GSK under existing sublicense agreements using its current allocation methodology.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 5,124 shares of common stock at $10.35 per share. After this transaction, he directly holds 247,926 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance as part of routine portfolio management.
REGENXBIO Inc. is a clinical-stage gene therapy company built on its proprietary NAV AAV platform, used in internal programs and by licensees such as Novartis’ Zolgensma and Itvisma. The company focuses its own pipeline on retinal, neuromuscular and neurodegenerative diseases.
Key assets include sura-vec (ABBV-RGX-314) for wet AMD and diabetic retinopathy, partnered with AbbVie, with two pivotal wet AMD trials fully enrolled and a Phase IIb/III DR trial (NAAVIGATE) expected to start dosing in 2Q 2026. RGX-202 for Duchenne muscular dystrophy is in the pivotal phase of the AFFINITY DUCHENNE trial, targeting an accelerated approval BLA in 2026.
RGX-121 for MPS II, partnered with Nippon Shinyaku, showed strong CSF biomarker reductions and enabled a BLA filing, but the FDA issued a Complete Response Letter and placed RGX-121 and RGX-111 (for MPS I) on clinical hold after a PLAG1-family CNS tumor case in the RGX-111 study. REGENXBIO emphasizes its in-house 2,000‑liter NAVXpress manufacturing platform and cGMP facility, as well as substantial collaboration and royalty revenues from AbbVie, Nippon Shinyaku and NAV Technology Licensees.
REGENXBIO Inc. reported strong revenue growth but continued losses for the quarter and year ended December 31, 2025. Full-year revenue rose to $170.4 million from $83.3 million, mainly from its Nippon Shinyaku collaboration and higher Zolgensma and Itvisma royalties. Net loss narrowed to $193.9 million, or $3.76 per share, from $227.1 million, or $4.59 per share. Cash, cash equivalents and marketable securities totaled $240.9 million, and the company expects this to fund operations into early 2027.
Late-stage gene therapy programs advanced, led by RGX-202 for Duchenne muscular dystrophy with positive 18‑month functional data and pivotal topline results expected in early Q2 2026. Sura-vec (ABBV‑RGX‑314) for retinal diseases is moving toward pivotal readouts and a potential $100 million AbbVie milestone upon first patient dosing in the NAAVIGATE trial expected in Q2 2026. However, the FDA placed clinical holds on RGX‑111 and RGX‑121 and issued a complete response letter for the RGX‑121 BLA, which the company is working to address.
REGENXBIO Inc. is registering up to $150 million of common stock for an at-the-market offering through Leerink Partners, which will act as sales agent for a fee of up to 3.0% of gross proceeds. Shares may be sold from time to time on Nasdaq under the symbol RGNX or in other permitted transactions.
The company estimates it held about $241 million of cash, cash equivalents and marketable securities as of December 31, 2025 and currently expects this to fund operations into early 2027. Despite this, REGENXBIO states that there is substantial doubt about its ability to continue as a going concern within 12 months of filing its 2025 Form 10‑K and anticipates an auditor opinion including a going‑concern explanatory paragraph.
Regulatory setbacks add to the risk profile. The FDA issued a Complete Response Letter for RGX‑121, outlining several scientific concerns, and placed clinical holds on RGX‑111 and RGX‑121 after a neoplasm was observed in one RGX‑111 trial participant. The company warns these issues, along with potential dilution—illustrated by a scenario where 17,647,058 shares are sold at $8.50 per share—could materially affect its business and stock price.
REGENXBIO Inc. reported that the U.S. FDA issued a Complete Response Letter for its Biologics License Application for RGX-121, an investigational one-time gene therapy for Mucopolysaccharidosis II (Hunter syndrome). The FDA cited concerns about defining the neuronopathic patient population, the suitability of the natural history external control, and using CSF HS D2S6 as a surrogate endpoint.
The letter outlines potential paths forward, such as a new study, treating additional patients with longer-term follow-up, or using an untreated control arm, which the company notes are challenging in this ultra-rare disease. REGENXBIO plans to request a Type A meeting and aims to resubmit the BLA after providing additional data and expert input.
REGENXBIO Inc. Chief Strategy & Legal Officer Patrick J. Christmas reported a routine tax-related share withholding. On February 1, 2026, 4,700 shares of common stock were withheld at $11.16 per share to cover taxes on vesting restricted stock units. After this transaction, he beneficially owned 210,667 shares of REGENXBIO common stock directly.